Esperion Therapeutics Inc (NASDAQ:ESPR) has been given an average rating of “Buy” by the sixteen ratings firms that are presently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $90.62.
A number of research analysts have recently issued reports on the company. BidaskClub downgraded Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $65.00 price target (up from $55.00) on shares of Esperion Therapeutics in a report on Wednesday, February 21st. UBS set a $90.00 price target on Esperion Therapeutics and gave the company a “neutral” rating in a report on Wednesday, February 21st. Needham & Company LLC raised Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and upped their price target for the company from $72.00 to $81.00 in a report on Thursday, December 14th. Finally, Chardan Capital upped their price target on Esperion Therapeutics from $20.00 to $75.00 and gave the company a “neutral” rating in a report on Wednesday, December 6th.
Shares of ESPR stock traded down $0.20 during trading hours on Friday, hitting $70.17. The stock had a trading volume of 557,153 shares, compared to its average volume of 709,905. The company has a market capitalization of $1,859.43, a P/E ratio of -10.00 and a beta of 2.45. Esperion Therapeutics has a 1 year low of $30.95 and a 1 year high of $82.68.
In other Esperion Therapeutics news, Director Nicole Vitullo sold 11,674 shares of the stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $71.79, for a total value of $838,076.46. Following the transaction, the director now owns 3,177 shares of the company’s stock, valued at $228,076.83. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 32.50% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of the business. Meditor Group Ltd lifted its holdings in Esperion Therapeutics by 1.2% in the fourth quarter. Meditor Group Ltd now owns 2,322,835 shares of the biopharmaceutical company’s stock valued at $152,935,000 after acquiring an additional 27,900 shares during the period. Millennium Management LLC increased its position in Esperion Therapeutics by 1,062.7% in the fourth quarter. Millennium Management LLC now owns 387,947 shares of the biopharmaceutical company’s stock worth $25,542,000 after buying an additional 354,580 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec purchased a new stake in Esperion Therapeutics in the third quarter worth about $12,583,000. Amundi Pioneer Asset Management Inc. increased its position in Esperion Therapeutics by 25.5% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 238,384 shares of the biopharmaceutical company’s stock worth $15,695,000 after buying an additional 48,485 shares in the last quarter. Finally, MUFG Securities EMEA plc purchased a new stake in Esperion Therapeutics in the third quarter worth about $9,022,000. 91.66% of the stock is currently owned by institutional investors.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.